Star Rating for Biosimilars Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Apr 26, 2021)
Star Rating for Biosimilars Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.
The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.
What just happenedApr 27, 2021
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseApr 26, 2021
- Apr 27, 2021Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Apr 26, 2021Committee
Referred to the Subcommittee on Social Security.
Social Security Subcommittee - Apr 26, 2021Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Apr 26, 2021IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Apr 26, 2021IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Apr 26, 2021IntroReferralIntro-H
Introduced in House
- Apr 26, 2021IntroReferral1000
Introduced in House